Best Practice Exchanges on the Clinical Management of Advanced Urothelial Cancer
Release date 13-02-2022
Expiration date 12-02-2023
The therapeutic landscape of advanced urothelial cancer has undergone significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors to the treatment armamentarium. In these Best Practice Exchanges on the clinical management of advanced urothelial cancer, experts in the field discuss clinical cases that are representative of the clinical course of the disease, and they review the evidence for neoadjuvant and adjuvant immunotherapy, first-line systemic treatment for metastatic disease, the role of maintenance immunotherapy, second line and salvage treatment options, as well as adverse event management.
This program is available with subtitles in the following languages:
Robert Coleman MBBS, MD, FRCP, FRCPE, FACP | Moderator
Emeritus Professor, University of Sheffield
Robert (Rob) Coleman is Emeritus Professor of Medical Oncology in the Department of Oncology and Metabolism at the University of Sheffield, UK. He graduated in medicine from King’s College Hospital Medical School in 1978 and trained in London and Edinburgh before moving to Sheffield in 1991; he was instrumental in developing clinical cancer research in Sheffield and established an internationally respected bone oncology research team in the city. Professor Coleman has held many leadership roles within the university and the National Institute for Health Research (NIHR) Cancer Research Network. He has published over 450 peer-reviewed manuscripts and numerous book chapters, and is a Past-President of the Cancer and Bone Society and the founding editor of Journal of Bone Oncology.
During 2014–2019, Professor Coleman was a part-time Medical Director for the global independent medical education provider, prIME Oncology, developing and delivering both live and online educational activities for oncologists and other providers of cancer care. Since retiring from his formal position at the university in 2017, he remains active in research, lectures on his areas of expertise around the world, and provides consultancy to a medical education company as well as a range of pharma and biotech companies developing new oncology treatments.
Ravindran Kanesvaran, MRCP (UK), BSc (Hons), MD, FAMS (Med Onco)
National Cancer Center Singapore
Ravindran Kanesvaran is a Senior Consultant and Deputy Head of the Division of Medical Oncology of the National Cancer Centre Singapore and Medical Director of NCCS Oncology @ SKH. He is also an Associate Professor at Duke-NUS Medical School and Clinical Senior Lecturer at the Yong Loo Lin School of Medicine, National University of Singapore. He is actively involved in graduate medical education and is the Program Director of the Medical Oncology Senior Residency Program. His research interests include genito-urinary oncology and geriatric oncology. He has published in a number of well-known peer reviewed journals, including Journal of Clinical Oncology and Lancet Oncology. He is also the author of textbook chapters in the field of geriatric oncology. He has been given a number of awards, including the American Society of Clinical Oncology (ASCO GU) Merit Award 2009, American Association for Cancer Research (AACR) scholar-in-training Award 2010, and European Society for Medical Oncology (ESMO) fellowship award 2012. He is currently the immediate past-President of the Singapore Society of Oncology (SSO) and the Singapore Geriatric Oncology Society. He is a member of the ESMO Council, the ESMO Asia Pacific Public Policy Committee Chair, and a member of the ESMO Leadership Generation Task Force. He is the President and the National Representative for Singapore in the International Society of Geriatric Oncology (SIOG). He is currently the Vice Chairman of the Singapore Cancer Society (SCS).
Yohann Loriot, MD, PhD
Yohann Loriot was appointed as Senior Lecturer and Consultant in Medical Oncology at Gustave Roussy, Villejuif, France, in 2013. He works in clinical drug development within genitourinary trials and has a particular interest in rationally designed molecular targeted therapies and immunotherapies in urothelial and bladder cancer. Dr Loriot graduated from the University of Paris in 2009 and completed a PhD in 2014. He was awarded a travelling scholarship and pursued further research at the Vancouver Prostate Cancer Centre in Vancouver, Canada. Dr Loriot received the prestigious ASCO Conquer Foundation Young Investigator Award in 2014. Over the last 5 years, Dr Loriot has been involved in the development of multiple novel agents, many of which are now approved drugs, and he is currently running over 20 clinical trials. Dr Loriot is currently a member of the steering committees of multiple international clinical trials from phase I to phase III, and a co-author of collaborative work, published in N Engl J Med, Nature, Lancet Oncology, European Urology, and J Clin Oncol. He has been involved in trials leading to several drug approvals (enzalutamide, abiraterone, atezolizumab, erdafitinib). Dr Loriot’s major research focus involves the study of molecular mechanisms mediating progression to lethal disease in bladder and prostate cancer and the use of this information to develop novel new strategies and therapies.
Deborah Mukherji, MD, MBBS, FRCP
Clemenceau Medical Center Dubai
Deborah Mukherji specializes in gastrointestinal and genito-urinary medical oncology and is a Vice-Chair of the Biomedical Institutional Review Board at AUB. In 2012, Dr. Mukherji joined the faculty of the American University of Beirut in Lebanon, where she is an Associate Professor of Clinical Medicine. She has also recently joined Clemenceau Medical Center Dubai, UAE. In addition, Dr. Mukherji has an interest in Global Oncology and leads the AUB Global Health Institute Cancer in Conflict Workstream for the R4HC-MENA research group (r4hc-mena.org) funded by UKRI.
Dr. Mukherji completed her advanced specialty training in Medical Oncology at Guy’s and St Thomas’ NHS Foundation Trust, London, UK, and was awarded a Post-Graduate Diploma in Oncology from the Institute of Cancer Research, University of London, in 2011. She is currently an ESMO faculty members for the genitourinary tumors prostate group and a member of the scientific committee for the ESMO World GI Cancer meeting. She is a commissioner for the Lancet Commission on Women and Cancer.
Günter Niegisch, MD, PhD
Düsseldorf University Hospital
Günter Niegisch is a Senior Staff Physician and Head of the Division of Genitourinary (GU) Oncology at Düsseldorf University Hospital, Germany. His clinical research includes evaluating systemic therapies for uro-oncological malignancies, especially urothelial carcinomas, with a focus on outcomes studies. Dr. Niegisch has been the Working Group Leader of the S3-Guideline for Bladder Carcinoma and Working Group 5 “Therapy of Muscle-Invasive Bladder Carcinoma” since 2012 and the Guideline Coordinator of the S3-Guideline for Bladder Carcinoma since 2021. He has been the Spokesperson of the Interdisciplinary Bladder Carcinoma Working Group (IABC) of the German Cancer Society since 2016 and Organ group spokesperson for “Penile Carcinoma” of the Urological Oncology Working Group (AUO) of the German Cancer Society since 2019. Dr. Niegisch has authored or co-authored over 250 publications in peer-reviewed journals.
Leonardo Oliveira Reis, MD, MSc, PhD
University of Campinas
Sao Paulo, Brazil
Leonardo O. Reis is Full Professor of Urologic Oncology and Urology at Pontifical Catholic University of Campinas (PUC-Campinas), SP, Brazil. He was also Professor Livre Docente (highest academic qualification in Brazil) in Urology 2018 UNESP and in Urologic Oncology 2021 UNICAMP. He completed post-doctoral fellowships at Johns Hopkins University, School of Medicine, Baltimore, US, and Columbia University, New York, US. His clinical practice specializes in minimally invasive genitourinary cancer treatment, with a particular emphasis on multidisciplinary knowledge frontiers and patient-centered values, with his main research interest being onco-immunology. Dr. Reis is an MSc and PhD mentor, and is passionate about uroscience and the teaching-learning process. He is an author of over 200 scientific publications and several books, and is Associate Editor of international peer-reviewed scientific journals World Journal of Urology and International Brazilian Journal of Urology. He is Principal Investigator/Co-investigator of international investigator-initiated sponsored research (IISR) collaborations on urologic oncology.
Maria De Santis, MD
Maria De Santis is a medical oncologist and Chair of Section for Interdisciplinary Genito-Urinary Cancer Medicine at the Charité Medical University Hospital, Berlin, Germany. She has been Associate Professor (Privatdozentin) of Medicine at Paracelsus Medizinische Privatuniversität in Salzburg, Austria, since 2008, and has worked as a senior consultant at the 3rd Medical Department, Center of Oncology and Hematology at Kaiser Franz Josef-Spital in Vienna for 18 years, where she has also led the Genito-Urinary Oncology Service for 11 years. From 2015 until April 2018 she was appointed Associate Clinical Professor for Oncology at the University of Warwick, Coventry, and also worked clinically in genitourinary oncology at the Queen Elizabeth Hospital, Cancer Centre, in Birmingham, UK. In addition, she was appointed Adjunct Professor in the Department of Urology at the Medical University of Vienna, Austria, in 2016.
Dr. De Santis is a member of several international scientific committees, including the European Society of Medical Oncology, the European Association of Urology, and the European Organization for Research and Treatment of Cancer. She also served as a scientific committee member of the American Society of Clinical Oncology for a 3-year term. She has authored multiple peer-reviewed articles in genito-urinary cancer medicine. In addition, Dr. De Santis is a panel member of the European Association of Urology (EAU) Scientific Office, the ESMO bladder cancer guidelines group, and the EAU Prostate Cancer guidelines panel. Her main research interests include prostate, renal, and bladder cancer.
Best Practice Exchange #1:
- Clinical case 1: Cisplatin-eligible first-line treatment for metastatic disease
- Clinical case 2: Locally advanced bladder cancer
Best Practice Exchange #2:
- Clinical case 1: Cisplatin-ineligible metastatic urothelial bladder cancer
- Clinical case 2: Second-line therapy for metastatic disease
Best Practice Exchange #3
- Clinical case 1: Cisplatin-ineligible metastatic urothelial bladder cancer
- Clinical case 2: Management of immune-related adverse events
These activities are designed for medical oncologists, urologists, and other healthcare professionals involved or interested in the management of urothelial carcinoma.
Upon completion of these educational activities, participants should be able to:
- Discuss efficacy and safety evidence surrounding the use of immune checkpoint inhibitors and antibody-drug conjugates for advanced/metastatic urothelial cancer
- Transfer knowledge into practice, and apply the available systemic treatment options to the management of patients with advanced/metastatic urothelial cancer
- Develop strategies to manage adverse events associated with immunotherapy for advanced/metastatic urothelial cancer
This educational activity is provided by ACE Oncology.
This educational activity is supported by an independent grant from Pfizer, and the Healthcare business of Merck KGaA, Darmstadt, Germany.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Ravindran Kanesvaran has served as an advisor or consultant for MSD, BMS, Astellas, J&J, Amgen, Novartis, AstraZeneca, Eisai, and Ipsen. He has served as a speaker or a member of a speakers bureau for MSD, BMS, Astellas, J&J, Amgen, Novartis, AstraZeneca, Eisai, and Ipsen. Professor Kanesvaran has received grants for clinical research from Sanofi, Eisai, and J&J. Any labeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Yohann Loriot has served as an advisor or consultant for Astellas, Pfizer, Merck, MSD, Janssen, Immunomedics, Seattle Genetics, Taiho, BMS, AstraZeneca, and Roche. Any labeled/unapproved uses of drugs and products referenced in his presentation will be specified.
Deborah Mukherji has served as a speaker or a member of a speakers bureau for Astellas, BMS, MSD, Bayer, and Janssen. She has received grants for clinical research from Astellas, BMS, and Merck. Any labeled/unapproved uses of drugs or products referenced in her presentation will be specified.
Günter Niegisch has served an advisor or consultant for Roche Pharma, Sanofi, BMS, Merck Serono, Pfizer, MEDAC, Ipsen, Janssen-Cilag, and AstraZeneca. He has served as a speaker or a member of a speakers bureau for Roche Pharma, MEDAC, Pfizer, BMS, and AstraZeneca. Any labeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Leonardo O. Reis has no financial relationship to disclose. Any labeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Maria De Santis has served as an advisor or consultant for AAA, Amgen, Astellas, AstraZeneca, Basilea, Bayer, Bioclin, BMS, Eisai, Ferring, Immunomedics, Ipsen, Janssen, MSD, Merck, Novartis, Pfizer, Pierre Fabre Oncology, Roche, Sandoz, Sanofi, and SeaGen. She has served as a speaker or a member of a speakers bureau for Amgen, Astellas, AstraZeneca, Basilea, Bayer, Bioclin, BMS, Eisai, Ferring, Immunomedics, Ipsen, Janssen, MSD, Merck, Novartis, Pfizer, Pierre Fabre Oncology, Roche, Sandoz, Sanofi, and SeaGen. Professor De Santis has received grants for clinical research from Pierre Fabre and has non-financial interests in EAU Prostate cancer guidelines panel, ESMO bladder cancer clinical practice guidelines, and S3 Harnblasenkarzinom Leitlinie. Any labeled/unapproved uses of drugs or products referenced in her presentation will be specified.
The employees of ACE Oncology have disclosed:
Robert Coleman has received consulting fees for advising on clinical trial protocol development and conduct from Amgen, AstraZeneca, Boehringer Ingelheim, ITM, Menarini, and Scancell. He is the Chair of the Inbiomotion Scientific and Clinical Advisory Board, and he also has intellectual property rights and stock options as a co-inventor and patent holder of a biomarker under development by Inbiomotion. He has given independent medical education lectures at symposia supported by Amgen, ITM, and Novartis.
ACE Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.